News

Martin Lehr 4/20/23 Martin Lehr 4/20/23

Development of CTIM-76, a highly specific Claudin 6 bispecific antibody for treatment of ovarian cancer

Joseph Rucker, Ileine Sanchez, Kyle Doolan, Breanna Tyrell, Anna Lobley, Nicholas Molino, Kristen Shema, Kyle Guldner, Hayley Roth, Alyssa Cunningham, Kate Slovik, Eric Butz, Evan Dick, Ross Chambers, and Riley Payne

American Association of Cancer Research I Abstract 1865 I April 14-19, 2023

Martin Lehr 4/15/22 Martin Lehr 4/15/22

Atomic-level Specificity of Claudin 6 Monoclonal Antibodies Isolated for Treating Solid Tumors

Brad Screnci, Lewis J. Stafford, Trevor Barnes, Kristen Shema, Samantha Gilman, Rebecca Rimkunas, Suzie Al Absi, Tim Phillips, Nick Molino, Charles Azuelos, Katherine Slovik, Paige Murphy, Daniel B. Harmon, Tom Charpentier, Benjamin J. Doranz, Joseph B. Rucker, Ross Chambers

American Association of Cancer Research I Abstract 318 I April 8-13, 2022

Martin Lehr 3/8/22 Martin Lehr 3/8/22

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.